Another Alzheimer’s setback as Amgen, Novartis abandon BACE inhibitor trial
Sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk.
Read More
Tag: failed
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
